Company Website:
http://www.genzyme.com
CAMBRIDGE, Mass. -- (Business Wire)
Genzyme,
a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the
launch of Expression of Hope III, a global program of inspiration and
awareness featuring works of art by the community of people affected by
lysosomal storage disorders (LSD). This unique program encourages anyone
affected by an LSD to create and submit a work of art that expresses
their experiences of living with a rare, inherited disease. Through the
Expression of Hope program, Genzyme furthers its long-standing history
of collaboration with patient advocacy organizations around the world to
help raise awareness and build a stronger global network of support for
people affected by LSDs.
“Being diagnosed with a lysosomal storage disorder often creates a sense
of isolation for patients and families,” said Jamie Ring, Genzyme’s vice
president of global patient advocacy and humanitarian programs, adding,
“Through Expression of Hope, anyone whose life has been touched by an
LSD – including caregivers, family members, and friends – is invited to
use the power of art to share their unique story with the world. Our
goal is to use works of art to help more people learn about the impact
of LSDs and join the effort to support people affected by them.”
The Expression of Hope program will be accepting submissions through
December 5, 2014. Submitted artwork that meets program guidelines will
be exhibited in the online gallery on the Expression of Hope web site (www.expressionofhope.com).
Select works of art will also be featured in art exhibitions and program
materials beginning in 2015.
Through Expression of Hope, anyone who has been touched by an LSD can
submit an original work of art on paper or canvas, such as a painting,
photograph or sketch. Artists of all ages and artistic ability,
including family members, friends and healthcare workers, can
participate. Once an artist has completed a piece, it should be
photographed and digitally submitted to the Expression of Hope website.
All submitted works that meet entry criteria will be presented on the
Expression of Hope website. When the submission period closes on
December 5, 2014, a panel of art experts will then identify submissions
to be designated as Featured Art, which will be displayed in global
exhibits and materials. LSD patient organizations around the world are
invited to participate in Expression of Hope by promoting the program in
their communities. To learn more about Expression of Hope or to submit a
work of art, visit www.expressionofhope.com.
Lysosomal storage disorders, also known as lipid storage disorders, are
a group of inherited metabolic conditions in which fatty materials
(lipids) accumulate in various cells and tissues in the body. People
with these disorders either do not produce enough of an enzyme required
to break down (metabolize) lipids, or they produce enzymes that do not
work properly. Over time, the build-up of lipids can lead to cellular
and tissue damage, particularly in the brain, peripheral nervous system,
liver, spleen, and bone marrow.1 Examples of LSDs include
Gaucher disease and Fabry disease.
About Expression of Hope
Expression of Hope is a global
program of inspiration and awareness featuring works of art by the
lysosomal storage disorder community. In collaboration with LSD patient
organizations around the world, Genzyme launched the Expression of Hope
program in 2006 to give those impacted by lysosomal storage disorders
(LSDs) the opportunity to raise awareness of these rare genetic
diseases. More than 100 patients and caregivers expressed their unique
stories through their original pieces of artwork. Building on that
initial success, Genzyme launched the second Expression of Hope program
in 2009, and once again the global community responded with enthusiasm,
creativity and insight. The third Expression of Hope program further
reinforces the commitment of individuals affected by lysosomal storage
disorders to building awareness and expressing their unique stories
through art.
About Genzyme, a Sanofi Company
Genzyme has pioneered the
development and delivery of transformative therapies for patients
affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the
compassion and commitment of our employees. With a focus on rare
diseases and multiple sclerosis, we are dedicated to making a positive
impact on the lives of the patients and families we serve. That goal
guides and inspires us every day. Genzyme’s portfolio of transformative
therapies, which are marketed in countries around the world, represents
groundbreaking and life-saving advances in medicine. As a Sanofi
company, Genzyme benefits from the reach and resources of one of the
world’s largest pharmaceutical companies, with a shared commitment to
improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All rights
reserved.
About Sanofi
Sanofi, a global healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients’
needs. Sanofi has core strengths in the field of healthcare with seven
growth platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s
ability to benefit from external growth opportunities, trends in
exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number
of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for
the year ended December 31, 2013. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
1National Institutes of Health, Lipid Storage Diseases
Fact Sheet
Contacts:
Media Contact:
Genzyme
Lori
Gorski, 617-768-9344
Lori.gorski@genzyme.com
Source: Genzyme
© 2024 Canjex Publishing Ltd. All rights reserved.